Biodistribution

Vesigen Highlights Data Demonstrating Directed Tropism of Non-Viral Delivery Platform at the 30th Annual Congress of the European Society of Gene & Cell Therapy

Retrieved on: 
Mercredi, octobre 25, 2023
Biotechnology, Health, Genetics, Science, Research, Gene editing, Delivery, RNA, Tropism, ARMM, Macrophage, Liver, ARMM Regional Legislative Assembly, Mouse, Cell, Gene, ESGCT, European Society of Gene and Cell Therapy, Genome, Biodistribution, Therapy, Vaccine

Data highlighted the first demonstration of cell type-specific targeting of ARMMs and functional delivery of base editing complexes across diverse human cell types.

Key Points: 
  • Data highlighted the first demonstration of cell type-specific targeting of ARMMs and functional delivery of base editing complexes across diverse human cell types.
  • The data were presented at the 30th Annual Congress of the European Society of Cell and Gene Therapy (ESGCT), taking place October 24-27 in Brussels, Belgium.
  • “The data we presented at ESGCT represent the first demonstration of directed tropism of our non-viral ARMMs delivery platform.
  • This important result expands upon the natural biodistribution of ARMMs and demonstrates that ARMMs can be engineered to selectively target cell types of interest,” said Paulash Mohsen, Chief Executive Officer at Vesigen.

GenScript Biotech Corporation Presents the 3rd Annual Gene and Cell Engineering Summit

Retrieved on: 
Mercredi, juillet 19, 2023
Biodistribution, Gene, Drug discovery, High, GenScript Biotech, Research, AAV, Editas Medicine, Messenger, Associate, Cell engineering, Berlin Center, Cell, ISCB Senior Scientist Award, Protein engineering, HSC, UCLA, Synthetic biology, Safety, Vaccine

PISCATAWAY, N.J., July 19, 2023 /PRNewswire-PRWeb/ -- GenScript Biotech Corporation, a world-leading biotech company offering comprehensive solutions in gene, peptide, protein, and antibody research, is pleased to announce the 3rd Annual Gene and Cell Engineering Virtual Summit on July 26, 2023. The event will kick off at 11:00 a.m. Eastern Daylight Time in collaboration with the prominent science networking site, Labroots.

Key Points: 
  • GenScript Biotech's 3rd Annual Gene and Cell Engineering Summit on July 26th, 2023, will gather top scientists to explore advancements in synthetic biology and biotherapeutics.
  • PISCATAWAY, N.J., July 19, 2023 /PRNewswire-PRWeb/ -- GenScript Biotech Corporation , a world-leading biotech company offering comprehensive solutions in gene, peptide, protein, and antibody research, is pleased to announce the 3rd Annual Gene and Cell Engineering Virtual Summit on July 26, 2023.
  • GenScript has cemented its place at the forefront of the gene and cell engineering sector through its extensive services, which include gene synthesis, mRNA synthesis, peptide synthesis, custom antibody generation, and protein engineering.
  • The summit promises to provide a dynamic forum for discussing ground-breaking innovations in gene and cell engineering and fostering collaborations between scientists globally.

MTTI Highlights Promising One-Year Follow-Up on EBTATE Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion

Retrieved on: 
Mercredi, juin 21, 2023
Oncology, Health, General Health, Radiology, Clinical Trials, Pharmaceutical, Biotechnology, GFR, Hyperkalemia, Carcinoma, Radiation, Nephrotoxicity, Biodistribution, Blood urea nitrogen, Dosimetry, Half-life, Creatinine, Overalls, Quality of life, Glomerular filtration rate, NET, Dicarboxylic acid, Vomiting, Serum albumin, MD, Patient, Cancer, Kidney, Creatine, Nausea, BUN, PRRT, Phosphorus, Dietary supplement, Safety

Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.

Key Points: 
  • Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.
  • A 4-hour long amino acid cocktail infusion reduces renal absorbed radiation dose, with significant side effects like nausea, vomiting and hyperkalemia.
  • EBTATE administration appears to be safe without amino acid infusion.”
    Chris Pak, President & CEO of MTTI commented, “Amino acid infusion impacts quality of life, access to care, patient compliance to treatment and overall treatment costs.
  • Evaluation of Safety, Biodistribution and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE (EBTATE) with and without Amino Acid Infusion.

NeuBase Therapeutics Selected to Present Two Oral Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting

Retrieved on: 
Mardi, mai 2, 2023
Abstract, Gene, Gene editing, Toxicology, Myotonic dystrophy, Dietrich Stephan, Pharmacokinetics, Immune system, Cell, Therapy, Society, Biodistribution, Pharmaceutical industry

PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting, which will take place in Los Angeles, CA and virtually on May 16-20, 2023.

Key Points: 
  • PITTSBURGH, May 02, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced two abstracts have been accepted for two oral presentations at the American Society of Gene & Cell Therapy (“ASGCT”) 26th Annual Meeting, which will take place in Los Angeles, CA and virtually on May 16-20, 2023.
  • Details of the oral presentations are listed below, and the full abstracts are available on the ASGCT meeting website .
  • Toxicology, Pharmacokinetics and Biodistribution of a PATrOL™-Enabled Investigational Genetic Therapy for Myotonic Dystrophy, Type 1

Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company

Retrieved on: 
Lundi, novembre 7, 2022
Oncology, Health, Infectious Diseases, Genetics, Pharmaceutical, Biotechnology, University, Hargreaves, Growth, SEC, Private Securities Litigation Reform Act, Drug discovery, Collectable, Lung, Ovarian cancer, Degenerative disease, Solution, Cancer, Annual report, Risk, Industry, Cooley LLP, Precision medicine, Forward-looking statement, Oncology, COVID-19, Genomics, Cloud computing, Genetic testing, Neoplasm, Form 10-K, Hand, Acquisition, NASDAQ, Webcast, Investor relations, Compliance, Legislation, Candidate, NSCLC, Reproductive health, Public health, JAMA Otolaryngology–Head & Neck Surgery, P.C, Laboratory, Overalls, Tissue, Therapy, Sale, Safety, Paclitaxel, Technology, Health, CEO, Review, Genetics, Biodistribution, H. Lee Moffitt Cancer Center & Research Institute, Investment, PK, Head, Research, Pharmaceutical industry, Vaccine, Risk management, Breast

Fulgent Pharma and Fulgent Genetics were previously both owned by Fulgent Therapeutics until 2016, when the businesses were separated ahead of the Initial Public Offering of Fulgent Genetics.

Key Points: 
  • Fulgent Pharma and Fulgent Genetics were previously both owned by Fulgent Therapeutics until 2016, when the businesses were separated ahead of the Initial Public Offering of Fulgent Genetics.
  • Fulgent Genetics track record of integrating acquisitions, strategic partnerships, and disciplined execution has been a key element in the companys growth.
  • Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health.
  • In 2016, Fulgent Therapeutics split into two separate entities - Fulgent Pharma and Fulgent Genetics - in order to better pursue their independent objectives.

Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

Retrieved on: 
Jeudi, septembre 29, 2022
HIV/AIDS, Regenerative medicine, Laboratory, Safety, Infection, California Institute for Regenerative Medicine, Gene editing, AAV, MD, CRISPR, Week, Biodistribution, HIV, Temple University, HIV-1, Industry, Berkeley, Patient, ATI, RNA, Viral load, CEO, Human polyomavirus 2, ART, CIRM, Degenerative disease, PML, Northwest Biotherapeutics, SAN, GLOBE, University, Genome, Pharmaceutical industry, Vaccine

The grant will provide Excision with important funding to advance the trial and potentially demonstrate the safety and efficacy of removing viral DNA from people affected by the HIV pandemic.

Key Points: 
  • The grant will provide Excision with important funding to advance the trial and potentially demonstrate the safety and efficacy of removing viral DNA from people affected by the HIV pandemic.
  • Excision recently reported the first participant in the EBT-101 Phase 1/2 clinical trial was dosed in July 2022, with initial findings indicating the therapeutic has been well tolerated to-date.
  • EBT-101 is a unique, in vivo CRISPR-based therapeutic designed to cure HIV infections after a single intravenous infusion.
  • This allows for the excision of large portions of the HIV genome, thereby minimizing potential viral escape.

Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

Retrieved on: 
Jeudi, septembre 15, 2022
Laboratory, Safety, Infection, Department, Policy, Gene editing, AAV, Entrepreneurship, Center, CRISPR, Comprehensive, Principal, Biodistribution, HIV, Week, Neurovirology, Temple University, George Washington University School of Medicine & Health Sciences, HIV-1, Achievement, Berkeley, Inflammation, Clinical trial, ATI, RNA, Physician, Viral load, Human polyomavirus 2, ART, Cell, PML, Protalix BioTherapeutics, SAN, Associate, Research, DNA, GLOBE, University, Washington University School of Medicine, Genome, Interest, Pharmaceutical industry, Vaccine, Medicine, Excision

The participant was dosed in July 2022, with initial findings indicating EBT-101 has been well tolerated to-date.

Key Points: 
  • The participant was dosed in July 2022, with initial findings indicating EBT-101 has been well tolerated to-date.
  • EBT-101 is a unique, clinical-stage in vivo CRISPR-based therapeutic designed to cure HIV infections after a single intravenous infusion.
  • This allows for the excision of large portions of the HIV genome, thereby minimizing potential viral escape.
  • EBT-101, the Companys lead program, is an in vivo CRISPR-based therapeutic designed to cure HIV infections after a single intravenous infusion.

Molecular Targeting Technologies, Inc. Features EBTATE Advances at The 2022 SNMMI Meeting In Vancouver, BC

Retrieved on: 
Jeudi, juin 9, 2022
Biotechnology, Health, Oncology, Clinical Trials, SNMMI, Large-cell lung carcinoma, PET, Cell death, Glioblastoma, Society, Cancer, Society of Nuclear Medicine and Molecular Imaging, Biodistribution, Nen language (Papuan), 2021 Essex County Council election, Dosimetry, Health, Molecular imaging, Medical imaging, Safety, BC

Molecular Targeting Technologies, Inc. (MTTI), a clinical stage oncology company, will highlight advances on its EvaTheraTM radiotheranostics platform at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Vancouver, BC, on June 11-15, 2022 (Exhibit booth #1715).

Key Points: 
  • Molecular Targeting Technologies, Inc. (MTTI), a clinical stage oncology company, will highlight advances on its EvaTheraTM radiotheranostics platform at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Vancouver, BC, on June 11-15, 2022 (Exhibit booth #1715).
  • The EvaThera platform includes EBTATETM (177Lu-DOTA-EB-TATE) for Neuroendocrine Neoplasms (NENs), Hrthle cell thyroid and nasopharyngeal cancers and EBRGDTM (177Lu-DOTA-EB-RGD) for glioblastoma multiforme and non-small cell lung cancer
    A video featuring the EBTATE story (see link below) will be released at the meeting.
  • MTTI is a privately held, rapidly growing, well financed, clinical stage biotech developing targeted radiotherapeutics and diagnostics for rare cancers.
  • We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders.

NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution

Retrieved on: 
Mardi, mai 17, 2022
Company, Disease, DM1, Medicine, Annual general meeting, Private Securities Litigation Reform Act, RNA splicing, U.S. Securities and Exchange Commission, Nasdaq, Myotonia, Patient, Therapy, Society, DMPK, Marketing, Research, Gene, CNS, Government budget balance, Intention, Plasma, Dietrich Stephan, Biotechnology, RNA, Muscle tissue, Muscle weakness, Risk, American Society of Gene and Cell Therapy, Mutation, Cell, PK, PNA, Tissue, GLOBE, Pharmaceutical industry, Biodistribution, COVID-19

NT-0231.F rapidly cleared the plasma, and each tissue evaluated displayed an extended elimination phase with tissue concentrations measurable for at least four weeks following a single IV dose administration.

Key Points: 
  • NT-0231.F rapidly cleared the plasma, and each tissue evaluated displayed an extended elimination phase with tissue concentrations measurable for at least four weeks following a single IV dose administration.
  • Sandra Rojas-Caro, M.D., Chief Medical Officer of NeuBase, said, We continue to build a robust and compelling data set potentially supporting a whole body treatment solution for DM1.
  • These PK and biodistribution data presented today show IV administration of our lead candidate results in exposure in the major tissues that are affected by DM1.
  • We have now demonstrated in preclinical models that our lead candidate NT-0231.F achieves clinically relevant molecular and functional rescue as well as whole-body distribution.

Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022

Retrieved on: 
Lundi, mai 9, 2022
Gene, PCSK9, U.S. Securities and Exchange Commission, Population, Private Securities Litigation Reform Act, NHP, Nasdaq, Therapy, GLOBE, Company, Biotechnology, Cardiovascular disease, Moyamoya disease, Toxicology, Durability, Patient, Biodistribution, Security (finance), Animal, Gene editing, Apolipoprotein, GLP, LNP, Conference, Liver, Technology, Research, Risk management, Vaccine, Medical device, Copper, Blood, ANGPTL3, Verve, Plasma

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that new preclinical data from its VERVE-101 program and GalNAc-lipid nanoparticle (GalNAc-LNP) delivery technology will be presented this week during an oral session at the TIDES USA 2022 Oligonucleotide & Peptide Therapeutics Conference. The full presentation can be found online here.

Key Points: 
  • Verve is advancing VERVE-101 initially as a treatment for heterozygous familial hypercholesterolemia (HeFH), a genetic form of atherosclerotic cardiovascular disease (ASCVD).
  • Updated data with the clinical formulation of VERVE-101 demonstrated potent and durable editing of the PCSK9 gene and reductions of LDL-C in non-human primates (NHPs), with follow up now out to one year.
  • In addition, data evaluating the companys proprietary GalNAc-LNPs to deliver base editors to the liver resulted in improved editing potency in wild-type NHPs, when compared to delivery of the editor with standard LNPs.
  • Verve has previously shown the ability of its GalNAc-LNP to deliver its ANGPTL3 base editor in NHP models of homozygous familial hypercholesterolemia.